Do formulation switches exacerbate existing medical illness? Results of an open-label transition to orally disintegrating risperidone tablets-Reference-Cited by-同舟云学术

Do formulation switches exacerbate existing medical illness? Results of an open-label transition to orally disintegrating risperidone tablets

Published:2007 Issue:5 Volume:22 Page:307-314
ISSN:0885-6222
Container-title:Human Psychopharmacology: Clinical and Experimental
language:en
Short-container-title:Hum. Psychopharmacol. Clin. Exp.

Author:

Chue Pierre,Prinzo Rosanna S.,Binder Carin E.

Publisher

Wiley

Subject

Pharmacology (medical),Psychiatry and Mental health,Neurology (clinical),Neurology

Reference35 articles.

1. Intramuscular Preparations of Antipsychotics

2. American Psychiatric Association. 1994. Diagnostic and Statistical Manual of Mental Disorders, 4th edn (DSM-IV). American Psychiatric Press: Washington (DC).

3. Patient preferences and sensory comparisons of three intranasal corticosteroids for the treatment of allergic rhinitis

4. Drug therapy in the elderly: what doctors believe and patients actually do

5. Acceptability and Disintegration Rates of Orally Disintegrating Risperidone Tablets in Patients with Schizophrenia or Schizoaffective Disorder

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Characteristics of Word Categorization in Children with High-Functioning Autism;Communication Sciences & Disorders;2013-12-31

2. Current Progresses on Nanodelivery Systems for the Treatment of Neuropsychiatric Diseases: Alzheimer’s and Schizophrenia;Current Pharmaceutical Design;2013-12-31

3. An In Vitro Analysis of Disintegration Times of Different Formulations of Olanzapine Orodispersible Tablet: A Preliminary Report;Drugs in R&D;2013-10-30

4. Expanding the Framework of Assessing Adherence and Medication-Taking Behavior;Journal of Pain & Palliative Care Pharmacotherapy;2013-04-26

5. Risperidone Release from Solid Lipid Nanoparticles (SLN): Validated HPLC Method and Modelling Kinetic Profile;Current Pharmaceutical Analysis;2012-10-01